Holen Sie sich die Stockscreener-App
2.84
1.79%
0.05
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ESPR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$2.79
Offen:
$2.77
24-Stunden-Volumen:
4.55M
Relative Volume:
0.93
Marktkapitalisierung:
$572.61M
Einnahmen:
$116.33M
Nettoeinkommen (Verlust:
$-209.25M
KGV:
-1.3396
EPS:
-2.12
Netto-Cashflow:
$-135.49M
1W Leistung:
+5.97%
1M Leistung:
+58.66%
6M Leistung:
+86.84%
1J Leistung:
+62.29%
1-Tages-Spanne:
$2.73
$2.89
1-Wochen-Bereich:
$2.37
$2.89
52-Wochen-Spanne:
$0.6925
$3.94
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Firmenname
Esperion Therapeutics Inc
Sektor
Telefon
734-887-3903
Adresse
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Vergleichen Sie ESPR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
2.84 | 524.22M | 116.33M | -209.25M | -135.49M | -2.12 |
|
ZTS
Zoetis Inc
|
148.20 | 66.22B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.10 | 48.29B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.81 | 43.99B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.93 | 22.45B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
405.02 | 17.93B | 2.99B | 1.21B | 1.13B | 25.06 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-18 | Eingeleitet | Goldman | Neutral |
| 2024-12-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-06-20 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-08-01 | Hochstufung | Northland Capital | Under Perform → Market Perform |
| 2023-06-15 | Hochstufung | BofA Securities | Underperform → Buy |
| 2023-03-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-03-16 | Herabstufung | Northland Capital | Market Perform → Under Perform |
| 2023-03-07 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2023-02-27 | Fortgesetzt | BofA Securities | Neutral |
| 2023-02-24 | Hochstufung | Jefferies | Hold → Buy |
| 2023-02-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-08-03 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2022-05-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-03-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-19 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2021-10-14 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-05-05 | Herabstufung | Stifel | Buy → Hold |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-11 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-02-12 | Herabstufung | Jefferies | Buy → Hold |
| 2021-02-09 | Herabstufung | Goldman | Neutral → Sell |
| 2021-01-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-11-10 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-09-29 | Fortgesetzt | JP Morgan | Underweight |
| 2020-08-11 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-04-01 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-03-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-24 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2020-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-09-16 | Hochstufung | Goldman | Sell → Neutral |
| 2019-05-29 | Herabstufung | Goldman | Neutral → Sell |
| 2019-05-06 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-04-26 | Hochstufung | Goldman | Sell → Neutral |
| 2019-03-13 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-01-07 | Bestätigt | Needham | Strong Buy |
| 2018-12-13 | Eingeleitet | Goldman | Sell |
| 2018-10-29 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2018-10-16 | Eingeleitet | BTIG Research | Buy |
| 2018-08-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-07-11 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2018-05-03 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-05-02 | Herabstufung | BofA/Merrill | Buy → Underperform |
Alle ansehen
Esperion Therapeutics Inc Aktie (ESPR) Neueste Nachrichten
Invesco Ltd. Acquires 157,647 Shares of Esperion Therapeutics, Inc. $ESPR - MarketBeat
Esperion Therapeutics, Inc. $ESPR Stock Holdings Lessened by Two Seas Capital LP - MarketBeat
Graham Capital Management L.P. Has $702,000 Holdings in Esperion Therapeutics, Inc. $ESPR - MarketBeat
Esperion: A Mixture Of Opportunity And Risk: Why I Would Hold For Now - Seeking Alpha
Why is Esperion Therapeutics Inc. stock going upEarnings Overview Summary & Risk Controlled Swing Alerts - Lancaster City Council
Is There Enough Volume to Lift Esperion Therapeutics Inc.2025 Geopolitical Influence & Smart Allocation Stock Tips - beatles.ru
Investors Buy High Volume of Esperion Therapeutics Call Options (NASDAQ:ESPR) - MarketBeat
Candlestick signals on Esperion Therapeutics Inc. stock todayJuly 2025 Review & Comprehensive Market Scan Reports - Newser
How sensitive is Esperion Therapeutics Inc. to inflationJuly 2025 Gainers & Free Community Consensus Stock Picks - خودرو بانک
Market reaction to Esperion Therapeutics Inc.’s recent news2025 Earnings Impact & Short-Term High Return Ideas - Newser
How does Esperion Therapeutics Inc. perform in inflationary periodsJuly 2025 Chart Watch & Safe Entry Point Alerts - خودرو بانک
Will Esperion Therapeutics Inc. stock recover after recent drop2025 Pullback Review & Weekly Market Pulse Alerts - Newser
Wellington Management Group LLP Has $1.10 Million Position in Esperion Therapeutics, Inc. $ESPR - MarketBeat
Combining machine learning predictions for Esperion Therapeutics Inc.Weekly Earnings Recap & Free Expert Approved Momentum Trade Ideas - Newser
Is Esperion Therapeutics Inc. forming a bullish divergenceJuly 2025 Gainers & Free Safe Capital Growth Stock Tips - خودرو بانک
Esperion Therapeutics Inc. stock chart pattern explained2025 Fundamental Recap & High Accuracy Investment Signals - Newser
Reversal indicators forming on Esperion Therapeutics Inc. stockPortfolio Performance Report & Fast Entry High Yield Tips - Newser
Top 2 Health Care Stocks That May Plunge This Month - Benzinga
Is Esperion Therapeutics Inc. still a buy after recent gainsJuly 2025 Analyst Calls & Risk Controlled Daily Trade Plans - خودرو بانک
Is this a good reentry point in Esperion Therapeutics Inc.Earnings Recap Report & Long-Term Safe Investment Plans - Newser
Published on: 2025-09-05 06:44:23 - Newser
Esperion Therapeutics shares rise 2.77% premarket after presenting at Cantor. - AInvest
Esperion Therapeutics’ Path to Profitability and Global Expansion in the Cardiovascular Space - AInvest
Best data tools to analyze Esperion Therapeutics Inc. stockMarket Movement Recap & Risk Controlled Swing Trade Alerts - Newser
Analyzing recovery setups for Esperion Therapeutics Inc. investorsJuly 2025 Gainers & Precise Buy Zone Identification - Newser
What the charts say about Esperion Therapeutics Inc. todayBuy Signal & Safe Capital Preservation Plans - Newser
Signal strength of Esperion Therapeutics Inc. stock in tech scannersWeekly Profit Analysis & Fast Entry and Exit Trade Plans - Newser
Why Did Esperion Therapeutics Inc (ESPR) Soar 15.23% on Positive Q2 Earnings? - AInvest
Using flow based indicators on Esperion Therapeutics Inc.July 2025 PreEarnings & Precise Buy Zone Identification - Newser
What institutional flow reveals about Esperion Therapeutics Inc.July 2025 Institutional & Long-Term Investment Growth Plans - Newser
Will Esperion Therapeutics Inc. benefit from macro trendsQuarterly Earnings Summary & Reliable Intraday Trade Alerts - Newser
Can Esperion Therapeutics Inc. scale operations efficientlyJuly 2025 Action & Fast Gaining Stock Reports - خودرو بانک
Developing predictive dashboards with Esperion Therapeutics Inc. data2025 Performance Recap & AI Driven Stock Reports - Newser
Should you hold or exit Esperion Therapeutics Inc. nowJuly 2025 Movers & AI Optimized Trade Strategies - Newser
Real time pattern detection on Esperion Therapeutics Inc. stockPortfolio Value Summary & Growth Focused Stock Pick Reports - Newser
Tools to monitor Esperion Therapeutics Inc. recovery probabilityJuly 2025 Reactions & Fast Exit/Entry Strategy Plans - Newser
Technical analysis overview for Esperion Therapeutics Inc. stockWeekly Trade Summary & Weekly High Return Forecasts - Newser
Is Esperion Therapeutics Inc. benefiting from innovation trendsQuarterly Profit Review & AI Powered Buy/Sell Recommendations - khodrobank.com
Using Bollinger Bands to evaluate Esperion Therapeutics Inc.Quarterly Risk Review & Safe Capital Growth Stock Tips - Newser
Detecting support and resistance levels for Esperion Therapeutics Inc.Market Performance Recap & High Accuracy Swing Entry Alerts - Newser
Published on: 2025-09-02 13:26:49 - Newser
Is Esperion Therapeutics Inc. stock ready for a breakout2025 EndofYear Setup & Accurate Entry and Exit Point Alerts - Newser
Finanzdaten der Esperion Therapeutics Inc-Aktie (ESPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.67%
0.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):